<SEC-DOCUMENT>0001144204-15-016152.txt : 20150316
<SEC-HEADER>0001144204-15-016152.hdr.sgml : 20150316
<ACCEPTANCE-DATETIME>20150316102333
ACCESSION NUMBER:		0001144204-15-016152
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150316
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150316
DATE AS OF CHANGE:		20150316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		15701462

	BUSINESS ADDRESS:	
		STREET 1:		617 DETROIT STREET, SUITE 100
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48104
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		155 GIBBS STREET
		STREET 2:		SUITE 412
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v404515_8-k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<B> SECURITIES
AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
March 16, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border-bottom: black 1pt solid; text-align: center">Nevada</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center">1-12584</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 33%; border-bottom: black 1pt solid; text-align: center">13-3808303</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction of incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Commission File No.)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(IRS Employer Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>155 Gibbs Street, Ste. 412</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Rockville, MD 20850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>617 Detroit Street, Ste. 100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Ann Arbor, MI 48104</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Mailing Address and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code:&nbsp;(734) 332-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">N/A&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-top: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 2.02 - Results of Operations and
Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 16, 2015, Synthetic Biologics,
Inc., a Nevada corporation, (the &ldquo;Registrant&quot;) issued the attached press release that included financial information
for its fiscal year ended December 31, 2014. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K.
The information contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference
into any of the Registrant&rsquo;s registration statements or other filings with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">(d)&nbsp;Exhibits.&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Exhibit 99.1&nbsp;</TD>
    <TD>Press Release issued by Synthetic Biologics, Inc. dated March 16, 2015.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt; border-top: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B> &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">SYNTHETIC BIOLOGICS, INC.</TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="width: 50%">Date: March 16, 2015</TD>
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid"> /s/ C. Evan Ballantyne</TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD> C. Evan Ballantyne</TD></TR>
<TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD> Chief Financial Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt; border-top: Black 1pt solid">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 29.7pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; text-decoration: underline; text-align: center"><U>Exhibit No.</U></TD>
    <TD STYLE="width: 91%; text-decoration: underline"><U>Exhibits.</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">99.1</TD>
    <TD>Press Release issued by Synthetic Biologics, Inc. dated March 16, 2015.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27.5pt"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v404515_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 48pt; width: 243.75pt"></P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Reports Year End
2014 Financial Results and Operational Highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>-- Steady Progress in All Programs;
Two Phase 2 Clinical Trials to Start in 2015 --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>-- Conference Call Today, March 16,
2015, at 8:30 a.m. (ET) --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><B>Rockville,
MD, March 16, 2015 &ndash;</B> </FONT><FONT STYLE="color: Blue"><U>Synthetic Biologics, Inc.</U></FONT><FONT STYLE="color: windowtext">
(NYSE MKT: SYN), </FONT>a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting
the microbiome,<FONT STYLE="color: windowtext"> today reported financial results for the year ended December 31, 2014, and provided
an operational update.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;During the past year Synthetic
Biologics made important advances in furthering our goal of building a late-stage, pathogen-specific, microbiome-focused portfolio
with strong opinion leader support and a solid investor base,&rdquo; said Jeffrey Riley, Chief Executive Officer of Synthetic
Biologics. &ldquo;This year we plan to initiate Phase 2 clinical trials in two programs &ndash; SYN-004, a preventive therapeutic
for <I>C. difficile</I> infection, and SYN-010, a treatment for irritable bowel syndrome with constipation (IBS-C), with topline
data expected from both programs by year end. In addition, we are making good progress with previously reported partnering discussions
on our relapsing-remitting multiple sclerosis (RRMS) program.&rdquo; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Clinical Programs Update</U> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SYN-004</B> is a first-in-class oral
enzyme preventive therapy designed to protect the gut microbiome from the unintended harmful effects of intravenous (IV) antibiotics,
for the <B>prevention of <I>C. difficile</I> infection. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Established Clinical Advisory Board and strengthened intellectual property portfolio</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Completed Phase 1a and 1b clinical trials; reported positive topline safety and tolerability data
from both studies</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Plan to initiate a <FONT STYLE="color: windowtext">Phase 2a clinical trial to evaluate gastrointestinal
(GI) antibiotic-degrading effects and safety (1Q 2015); expect </FONT>topline data (1H 2015)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Presenting poster of late-breaking preclinical data for protection of microbiome at Digestive Disease
Week&reg; (May 2015)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Plan to initiate a Phase 2b proof-of-concept clinical trial (2H 2015); expect topline data (2H
2015)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SYN-010</B> is a proprietary, modified-release
statin formulation optimal for reducing methane-production by certain microorganisms in the gut to treat the underlying cause of
pain, bloating, and constipation associated with <B>IBS-C</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Established Clinical Advisory Board and
strengthened intellectual property portfolio </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A 505(b)(2) regulatory pathway is anticipated
for development</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Poster presentation of preclinical data
by lead principal investigator of Cedars-Sinai Medical Center at Digestive Disease Week&reg; (May 2015)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expect to submit an Investigational New
Drug (IND) application to initiate clinical trials (1H 2015)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Plan to initiate Phase 2 clinical trials
(2Q 2015); expect topline data (2H 2015)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SYN-005</B> is a novel combination of
two monoclonal antibodies designed to treat <B>Pertussis (whooping cough)</B> by targeting and neutralizing pertussis toxin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Strengthened intellectual property portfolio
</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reported positive preclinical research
findings from non-human primate studies</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted U.S. Orphan Drug designation by
the FDA</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Seeking non-dilutive funding to support
clinical development (ongoing)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Trimesta<SUP>TM</SUP></B> (oral estriol)
may offer a differentiated mechanism of action in the treatment of <B>RRMS</B>, as demonstrated in clinical trials. Based on Phase
2 clinical findings, Trimesta may offer both anti-inflammatory (decrease in relapse rate) and neuroprotective (improvements in
disability and cognition) benefits for patients with MS when taken in combination with Copaxone&reg;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expanded efficacy and safety results from
the investigator-initiated Phase 2 trial evaluating adjunctive Trimesta in women with RRMS including positive results on cognitive
and disability scores at 12 months, attesting to Trimesta's unique neuroprotective properties, were presented at the ACTRIMS-ECTRIMS
meeting in Boston in September 2014 by the trial's lead investigator.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Strengthened intellectual property portfolio
</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As previously disclosed, active discussions
with a number of potential strategic partners may accelerate development of Trimesta (ongoing)</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">MRI brain scan analyses underway to evaluate changes in the brain that correlate with improvements
seen in clinical outcomes; topline data expected from the principal investigator during the first half of 2015</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A separate multi-center U.S. Phase 2 trial
is underway focused exclusively on cognition utilizing Trimesta with a variety of currently marketed MS drugs, including Copaxone&reg;,
Avonex&reg;, Betaseron&reg;, Extavia&reg;, Rebif&reg;, Gilenya&reg;, Aubagio&reg; and Tecfidera&reg;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Year Ended December 31, 2014 Financial
Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses were
$6.0 million for the year ended December 31, 2014, compared to $5.8 million for the same period in 2013. This increase is primarily
the result of supplemental compensation granted by the Board of Directors to executive officers and increased stock-based compensation
expense during the year ended December 31, 2014, which was offset by the decrease of bad debt expense of $763,000 associated with
the note and interest receivables from the sale of Adeona Clinical Laboratory that were determined uncollectible during the year
ended December 31, 2013. Non-cash charges related to stock-based compensation were $1.6 million for the year ended December 31,
2014, compared to $1.3 million for the same period in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses increased
to $14.5 million for the year ended December 31, 2014, compared to $6.5 million for the same period in 2013. This increase of 123%
is primarily the result of increased program costs associated with expanded clinical development, manufacturing and research activities
within our pathogen-specific, microbiome-focused pipeline, including the Company&rsquo;s <I>C. difficile</I>, IBS-C and Pertussis
programs. Non-cash charges related to stock-based compensation were $803,000 for the year ended December 31, 2014, compared to
$375,000 for the same period in 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income was $718,000 for the year
ended December 31, 2014, compared to other income of $21,000 for the same period in 2013. The increase in other income is primarily
due to non-cash income of $620,000 from the change in fair value of warrants for the year ended December 31, 2014. The decrease
in fair value of the warrants was due to the decline in our stock price and the reduction in the time to maturity. There was no
non-cash income or expense relating to fair value warrants for the year ended December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash at December 31, 2014 was $17.5 million
compared to $14.6 million at December 31, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Conference Call</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics will hold a conference
call today, Monday, March 16<B>, 2015, at 8:30 a.m. (ET), during which Mr. Riley will provide an operational update and </B>C.
Evan Ballantyne, Synthetic Biologics' Chief Financial Officer, will review the Company's financial results for the year ended December
31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interested parties should call 1-888-347-5280
(U.S. toll free), 1-855-669-9657 (Canada toll free), or +1 412-902-4280 (International), fifteen minutes before the start of the
call to register. Registered callers on the toll free line may ask to be placed in the queue for the Question &amp; Answer Session.
The call will also be webcast over the Internet at <FONT STYLE="color: Blue"><U>http://www.videonewswire.com/event.asp?id=101639</U></FONT>.
If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL, <FONT STYLE="color: Blue"><U>http://www.videonewswire.com/event.asp?id=101639</U></FONT>,
for 30 days after the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE MKT: SYN)
is a clinical-stage biotechnology company developing pathogen-specific therapies for serious infections and diseases, with a focus
on protecting the microbiome. The Company is developing an oral biologic to protect the gut microbiome from intravenous (IV) antibiotics
for the prevention of<I> C. difficile</I> infection, an oral statin treatment to reduce the impact of methane producing organisms
on irritable bowel syndrome with constipation (IBS-C), and in collaboration with Intrexon Corporation (NYSE: XON), a monoclonal
antibody combination for the treatment of Pertussis. In addition, the Company is developing a Phase 2 oral estriol drug for the
treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic
Biologics' website at <FONT STYLE="color: Blue"><U>www.syntheticbiologics.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release includes forward-looking
statements on Synthetic Biologics&rsquo; current expectations and projections about future events. In some cases forward-looking
statements can be identified by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot;
&quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot;
and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number
of risks and uncertainties, many of which are difficult to predict and include statements regarding the planned Phase 2 clinical
trials, expected date of topline data from clinical trials, the expected date of submission of IND application for SYN-010, and
the 505 (b)(2) regulatory pathway anticipated for development of SYN-010. The forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements.
Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics&rsquo; forward-looking
statements include, among others, a failure to receive the necessary regulatory approvals for commercialization of Synthetic Biologics&rsquo;
therapeutics, a failure of Synthetic Biologics&rsquo; clinical trials, and those conducted by investigators, to be commenced or
completed on time or to achieve desired results, a failure of Synthetic Biologics&rsquo; clinical trials to receive anticipated
funding, a failure of Synthetic Biologics&rsquo; products for the prevention and treatment of diseases to be successfully developed
or commercialized, Synthetic Biologics&rsquo; inability to maintain its licensing agreements, or a failure by Synthetic Biologics
filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics
undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future
events, or otherwise, except as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics: Kris Maly, VP, Corporate
Communication, (734) 332-7800, <FONT STYLE="color: Blue"><U>info@syntheticbiologics.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Media: Wendy Emanuel, Wellspring Communications,
Inc., (773) 255-9580, <FONT STYLE="color: Blue"><U>wendy@wellspringcom.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- Financial Tables Follow -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I><BR CLEAR="ALL">
</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Synthetic Biologics, Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>(in thousands, except share and per
share amounts)</I></B></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font: bold 10pt Times New Roman, Times, Serif">Condensed Consolidated Balance Sheets</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="8" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Cash and cash equivalents</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">17,525</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">14,625</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,548</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,591</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">65</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">37</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Deposits and other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,144</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,257</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities and Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Current liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9,588</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,027</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Synthetic Biologics, Inc. and subsidiaries equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,556</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">15,230</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,144</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">16,257</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Condensed Consolidated Statements of Operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For the years ended<BR> December 31,</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Costs and Expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;General and administrative</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">6,013</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif; text-align: right">5,832</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,489</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,507</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Operating Costs and Expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">20,502</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,339</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss from Operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(20,502</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(12,339</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other Income (Expense)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Change in fair value of warrant liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">620</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">33</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Other income (expense)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">95</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(12</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Other Income, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">718</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>Net Loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(19,784</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(12,318</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net Loss Attributable to Non-controlling Interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(19,784</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(12,317</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share - Basic and Dilutive</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.32</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.27</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share Attributable to Synthetic Biologics, Inc. and Subsidiaries</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.32</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.27</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding - Basic and Dilutive</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">61,945,356</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">45,667,813</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`9`!D``#_X0O$17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````<````<@$R``(````4````CH=I``0````!````H@```,X`#T)````G
M$``/0D```"<0061O8F4@4&AO=&]S:&]P($-3,R!7:6YD;W=S`#(P,3$Z,3(Z
M,3@@,3`Z,C@Z,34```.@`0`#`````0`!``"@`@`$`````0```D^@`P`$````
M`0```8H`````````!@$#``,````!``8```$:``4````!```!'`$;``4````!
M```!)`$H``,````!``(```(!``0````!```!+`("``0````!```*CP``````
M``!(`````0```$@````!_]C_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+#!D2
M$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_VP!#
M`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``?`*`#`2$``A$!`Q$!_\0`'P``
M`04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0`
M``%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8
M&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)
MRM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!
M`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$
M!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I
M*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W>\OH+&,-,QRQ
MPJJ,EC["JIU"^DB,EOIC.,C:'E"$CUZ'V_.HJ.48-Q5WV*@HN24G9!_:WDJS
M7ME<6JHNYG(#IU`QE23W]*O0SQ7,2RP2I+&WW71@P/XBBE.4X\SBUZE5*?)L
M[KNB2L'Q5XLT_P`):<EU>[Y))6*PP1XWR'OU[#C)[9'J!5F9S5O\47MK^WM_
M$7AR^T:.Y($4TK$KG(R3N5<`9&<9QZ5LZ'XV@U7Q%>Z#=V4FGZC;=(I7SYH'
M4KP,\8(]0<C@4`5;CXAVZZYJNFV>G372Z7;RSW-P)`JKY:Y8#/).<+]?89J]
MX.\:V/C&UN'MXGMY[=@)()#D@'HP(Z@X(_#Z9`,U_B([S:O#9>'[Z]ETV\%J
MZ6_SLV3(-^`#@?N__'A6;!\69+J]ELK?PIJ<UW%GS((_F=,'!RH7(P2!0!N:
M5X[34O%2Z`^EW%K<_9TG<RM@H6C5]I7&01NQ^%7-?\6PZ!K>C:9):/,VIS")
M75@!&=RKDCO][]*`.<B^*<MW=W5O8>%M3O3;.4D-N"^WD@9PIQG!_*K0^(&J
M&!Y/^$(UP%650ODMDY!Y^[VQ^M`%*V^*T]Y<3V]KX2U6>>!MLT<0+-&<XPP"
MY!R#U]*V=,\=QZAXK3P^^F3VUP;=)W,K8*%HEDVE<9!&[!]Q0!F7GQ1$M]-;
M^'?#]]K:0'$LT`8(">F,*Q(.#R<=#C-=!X2\9:?XOM9I+2.6&>W*B:&4<J2.
M""."."/7CH*`)M151K]L\H_=^6,$CC@G/Z5N4`%9%YIDEK(]]I`$=R2#)!G$
M<X]QT!_VAS]<U479Z[%PE9V>S+6DZI!J]A'=VYX8#<A8$H2`0#@]P01[$'O7
M)?$;3M#U;^R;+4=4?3=2DF(T^98G<%B5#*<<#G9R2,<'.,YGT%.+A)Q9RWB&
MZ\7^$[6UE\3II'B'2C,(U2>)7*M@D<E00Q4-\Q##KGWO?%&S%O;:7XTTF9[2
M^1D0NH*LZLI*D^XY!!'(;!X&*"2YH'AZ#0_@_J4Z$/<ZAI<MU-)CG#0DJOK@
M`_F6/>N0T>RN?"_AG0?'6EH7"^9#J4.\@2(964'^0]B$.#S0!U7PLNX;_P`2
M>,[RW;?!<7B2QM@C*L\Q!P>G!JCX&_Y+/XG_`-VY_P#1Z4`4=7M];N?C;J4?
MA^\@M+_RD(EF`*[?)3(Y5OY5'K=GXIM/''A(>)M2M;UFOH_(-NH&T>8F[.$7
MV]:`*W@NS\5W>L>(?^$8U*TLMMPOVC[0H._+2;<?(W3YO3K7KOABV\06NFR)
MXDO;>\O#,2DENN%$>%P/NKSG=V[T`<7\.O\`DH'C7_K\;_T;)6%KR22?%CQ,
MD2LTC:5,$5!DD_9!@#'>@#K_`(0RV+^!8H[4K]H2:3[4!G.\G@G_`(!LY'''
ML:T=#U7PW=^,=5L]+T[9J4`?[5=I`JJYW`,-P.2=WJ.=IH`Z&_M&N[<K%((9
MQ_JY=N2GKC\*PK;6[C2KC[)K"N"3A'Z@XZE3_$.1[CTKAQ,YTJD:M_=V:_4B
M3<7?H;]M?VEYC[/<1R$C.T-R![CJ*CO]4LM,CWWEPL0*EE!ZL!C.!W/(XKNI
M-5K>SUN34K4Z<'4F[)'%_#:.Y6[URXQ$UA=W`EA:WD0Q*W)8;`Q*$ADX(S@#
M-;WBW1-`U^R2TUMUC,:O-%,'"/$JXWL">B\KG/'3/:IA"<%RS5FCT,=6HUZS
MJT'>+2_)7_$R8OA=I#7%K)?ZCJNI0VO$-O>7(>-1C&,``XX'`('`SQQ6_P")
M/#UCXKTLZ;>33)$LJN3`P#!@.!R#V/I5'(/FTNQMO"O]BS3O'9?9!8^8S`.5
M*B,<XQN.0!QR2..U1Z%H>F:?X731;61KO3U66(^:P8L&9MZM@`=2P(QQC%`%
M/PKX.TKP=+=1V%S<R/>!69;AU)PF>5PH_O\`/X4_2?!>G:/XGO\`7[>:Z:ZO
M0XD21U*#>P8X`4'J!W-`$<7AW1H_'4^OI>RG4Y`(7A,B^6#Y:_+C&=VP!L9S
M@YZ5:UKPI8Z[JVE:E=2W"3:;*)85B90K'<K?-D$D94="*`.3;X3>%=1O;B1-
M3U%Y68R.J31\9)_V.F01^!]*Z+PUX0TGP-!?SVMU<F*95>9[J12$5`QSD*,#
MYCG-`%K1?"=AH6L:IJ=K+<O/J4ADF65E*J2Q;Y<`$#+'J359?#6CP>.G\0?;
M)AJ<RA/(,B[/]7MP!MSG:A/7L3T%`&7??"C0+J^FNK6:^TXS`B2*SE"H0?O`
M`J<`^G3VK:\*>']#\-VTUCI!#R9#7$CL&E?D@%B,<`A@,`#(;OF@#H*BN(8;
MB%HKB))8SU1U#`_@:32:LP.2OM!T!+A8Q=7EJ3P$C<L#_P!]*V*F3P7I]U8>
M1<7=U,O_`"S<%4*`G)&`,'/<D$\#TK/"T8X6K[6EN<5?`TJT7&5[,Z.PT^TT
MRS2ULH$@@3HB#]3ZGW-5=4T.UU=B;AI`3:S6OR$#"R[-Q&0?F&P8/UZUM*3D
M[O<ZXQ48J,=D:=,2)8WE<$YD8,<^N`/Z4BAES`;B'8LK1L&5PP`/*D'!!['&
M#WP3@@\TVQLTL;<PHS,&EDE);'WG<N>G;+''MZT`.:W1KR.Y);?'&\8';#%2
M?_01^M34`4#IBM=Q3-.Y2&=KB*/`^5V1D(SC)7YV..N3UQ@"_0!GZ=I*Z:(8
MXKB<V\$(@AA+?*J#&,^K#&,^GODFQJ%E'J.FW5C,S+%<PO"Y0X8!@0<9[\T`
M6*IQZ>(+Z:XBF=%GD$LT>`0[!`@Y/085>!W`Z<@@%RJEG8)9SSR(YQ*<[``J
M@[F8G`XW$L<MC)`7.2,D`__9`/_M$GQ0:&]T;W-H;W`@,RXP`#A"24T$)0``
M````$``````````````````````X0DE-!"\``````$K;`0$`2````$@`````
M`````````-`"``!``@`````````````8`P``9`(````!P`,``+`$```!``\G
M`0!L;'5N`````````````#A"24T#[0``````$`!D`````0`!`&0````!``$X
M0DE-!"8```````X`````````````/X```#A"24T$#0``````!````'@X0DE-
M!!D```````0````>.$))30/S```````)```````````!`#A"24T$"@``````
M`0``.$))32<0```````*``$``````````CA"24T#]0``````2``O9F8``0!L
M9F8`!@```````0`O9F8``0"AF9H`!@```````0`R`````0!:````!@``````
M`0`U`````0`M````!@```````3A"24T#^```````<```________________
M_____________P/H`````/____________________________\#Z`````#_
M____________________________`^@`````________________________
M_____P/H```X0DE-!`````````(``3A"24T$`@``````!``````X0DE-!#``
M``````(!`3A"24T$+0``````!@`!````!CA"24T$"```````$`````$```)`
M```"0``````X0DE-!!X```````0`````.$))300:``````-)````!@``````
M```````!B@```D\````*`%4`;@!T`&D`=`!L`&4`9``M`#$````!````````
M``````````````````$``````````````D\```&*````````````````````
M``$`````````````````````````$`````$```````!N=6QL`````@````9B
M;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG````````
M``!,969T;&]N9P``````````0G1O;6QO;F<```&*`````%)G:'1L;VYG```"
M3P````9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI8V4````2````
M!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P`````````&;W)I9VEN
M96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E9`````!4>7!E
M96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J8P````$`
M``````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````
M`````$)T;VUL;VYG```!B@````!29VAT;&]N9P```D\````#=7)L5$585```
M``$```````!N=6QL5$585`````$```````!-<V=E5$585`````$```````9A
M;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O;`$````(8V5L
M;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/15-L:6-E2&]R
M>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%4VQI8V56
M97)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T````115-L
M:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L;VYG````````
M``IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N9P``````
M```+<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P````!/_``````
M```X0DE-!!0```````0````'.$))300,``````PP`````0```*````!K```!
MX```R*````P4`!@``?_8_^``$$I&248``0(``$@`2```_^T`#$%D;V)E7T--
M``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48
M$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+
M"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!K`*`#`2(``A$!`Q$!_]T`!``*_\0!
M/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0``````
M```!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3
M(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T
M-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=7
M9W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!
MD12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T
M9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7
MI[?'_]H`#`,!``(1`Q$`/P#U5))))2DDDDE*22224I))))2DDDDE*22224I)
M)))2DDDDE*22224I))))3__0]522224I))))2DDDDE*22224I))))2DDDDE*
M22224I))))2DDDDE*22224__T?54DQ(`D\*BSJ-N386X=.^MI@W/.UO]AL.<
MY)3?25`V]:9N+L>BYLG:&6N:Z.W\Y5L_Z:G5U7&=D?9;@_&R"2&5W#;OCO19
M[JK_`/K=GJ)L)<5T)"M[C**\XY#727]TB7X-Q))5>I]0Q^F=/R.H9,^CBUNL
M>&B7$-'T6#3WO^BQ.6-I)<+_`,]OK9^S_P!N?L*H]'C?(R)MV3L]71N[9N_[
MK_R_YG]*K;/K\T=4Z?7?C"KI'5ZVOP\YSB'!SHK=1DT%FQEE&3^@OV7O9^FH
MN_F_424]>DN;ROK7<?K33]7.EXS<IX`=G9#GEK:&Z/L]K:W[W5U.K_/9^FR<
M>G_2>G7^J'U[K^L.39AY..W#RMGJT,;87BQ@_G1N<RK]+5[?9_H_^+L24]8D
MN0_YX]<R,SJN'TSI+,R[IF2RD,%X875N.0UU[O58UK-CL>O]'[_YU5*/KU]:
M<G,R,#&Z`RW-Q/Z10,IH+.VKGUMK=S_@WO24]TDN;Z/]:<W.^L=_0\K#;C/Q
ML5F18X6;W"QS,6RR@MV;/T;\M[/4;9_@E+JGUIOP?K/C=#;C-LKR,9^0;R\A
MP+695GI^GL=_W#^EO_PB2GHDEPW3/KO];.JX@S.G_5YF303M+VY36C<`"YNV
MUE;_`&[E;R?K+]<\?'9D.^K@#6U/MR2<ID5['6:<'?\`H*V7>W_2)*>N27'=
M#^N'UEZP_&NHZ&T].NM%=N8W(:0QH=LNL]*QE=C_`$OZJ73O\8=-GU:R.N]0
MQA0:LC[-3CU/WFQYKKO8&OL;3L_G'^I_HZJO424]BDN&M^NWUKP\5O5NH=`%
M72'02X7#U6,=]!]C7@.;_P!>HQ_^$]%=CT_/Q>I8-&?B/]3'R6-LK=Y.$P[]
MU[?HO8DI_]+U'(K=9CVUM^D]CFCXD0JO1S^IM:6EI&L'_-/_`$V.5Y974NF9
M1R#G8+YO@;J7&`0WZ/I/_P`'9_QGZ*W_``B9EG.,;C#CUUC='A\$$UTMU4+*
MQ<?+I=1DUMMJ?RUP_$?NN;^:]95'UEH;9]GSV.QL@<M<T@_'TS[_`/MGUZ_^
M$5P]:Z;Z=CVW!_IL=8Y@!W;6\Z.V_P!5#'GQS($9>HFN$^F?%VX4>[$:\0%:
M[U5-7!SG874OV)FY`ML>WU,%[R?5LK_2;J[?;LLLQVT_SV_])_A/?[["_67)
MP,7H6;=U+'LR\$5[<FBH`O-;R*K")?3M]-K_`%'V>JSTV?I%SF1DCK_ULP+,
M%[F'ISMQ:YKBTU_2LLWU-<VCU8]#9?9_H/\`A]G6]0RJ,3"MR,AN^EC?>T09
M!.R/TA97^=_A';%+*,XR(G'A.E>,2RRG@R8\67#D&3W(GW*_0R1EP_U?F^9\
MY9T]F!T5W6_JU]9;L;'8SUAT_*>PN#XW/Q7UAQQ_M>[]'Z?V6[UK?\)_A5L9
MG_93_BY/4NI,:,NBF[)KL:(!?C&UGJ-9/\WF4U;;&?N7^S_!J_A?4WZD]1:W
MJ-72JAO<\;22&2QSJGM]&JQV+Z>]COYO]"];M]>"]@Z/94#1D8]C?1`BOT6>
MG195[=NSVY#&L:U!8\W_`(MNFTU]&=UAY-N;U.RQUUKR7.VUV64MKWN)<[<]
MMF18_P#PEMW]1<CT#HV9D_5/]M]*);U?HV:^VC:)=94*L=UM!`]UG+WLK_PG
MZ?&_[5+T^JCIW0NF&O&J]##Q@YS::P7:N<;'-K;JYS[+;/\`/0?J_A]*P<6[
M%Z9AG`;7<?7QC$MM+*W27,?=6[?0:'?H[7_]N>HDIY7_`!<YC,_KG7\]C=C,
MPT7M:3NC>[)=MW#Z2)]5?_R@_6+X?]^8NEP^F=$Z-F'[#B-QKNI.(>ZH0'%@
MLR/<)VL;[K=NQ'Q>B]*Q,_(ZCC8[:\S+_I%PG<_6?=KY)*>%NZ5D]5_QB]7Q
M<;.NZ:]M3;#D8Y(>0*\)GHF"S]&[U-__`%M!NZ7D]*^O.#BY.==U*QV'=8,C
M()+P'4=09Z(ES_T;/3W_`/7%VF(SHHZ[=G48;J\W*+\9W4"/;:ZG8V[';[R[
M=7]E_/IKW_9;/35CJ'2NB')/6\ZAAR,2E[?M)W%S:0VWU6PW_@[[_P`W\])3
MYO\`5#$KNZ,Q[OK._H9#R/L;;:ZP=&?I]EKV/_2+NV>DWZGY5574?VOZ6-D,
M=G;VV%[MMCCO?6Y[=S-VQ5<#ZH_4W,8^.CLI=2[TWUV$%P,-=_@;KF?G?O[U
MK5=-Z/TO#9TK'QA5B9KWU&EDEI-C+++=\NW;7UUO24XO^*__`,2=7_'7?]65
MY_11;_S*IS=AMQ\/JV[(8.-KL?%:QS_S6M<_]7]W_<A>Q=-Z9T_I.(,3I]+<
M;&:2X5MF`7>YY]Q*H]`PNBUX%N+T_IQQ<#)`M++&@UW,M;Z?J;2^[^<IJ;ZE
M-WIV_P"FI24AZI]<_J_B]%?U*O(IS&N9-6,U[0^PG_!.K=[ZO^']6O\`0?X5
M:/0\QV?TG%S78WV+[16+!C$@EK7>ZN=K6?39^D^BL;*^J7U,Z2#U-W2F.-;F
M^T2Y@)<&M=Z5]GV2JNN=WJ6^G32NCHN;?17>T%K;6AX!B0'#=KM+FI*?_]/U
M5))))37R\>O(J-=U%>0SG9:`6S_::]9]'U<Z6VP7?8VT6#_16V`1^[M8:F;/
MY&Q;"2!C$FR`3Y(,0=P"AQL3&Q6N;C5,I:]V]S6`-!=`;NVM_JI\G'IRJ747
M-W5OB0"6G0[FEKV%KV.:X?2:BI)Q))LZJ``%`4/!%C8M&+5Z-#=K)<XR2XES
MR7V/>]Y<][WO=NW/4C34;FWELVL:YC7>#7ECK&_VG4UJ:2"4=]%612^B]HLJ
MM:6/8>"TZ."CBXE&(PLI!&]V][GN<][G0&[K+;7/ML=L:QGO?_-L]-&224@R
ML+'R_3-P=NI=OK<Q[ZW`D%A]]+JW_1<CI))*:M?3,*K+=F,KBYVXSN<6@OCU
M7UTEWHUV6[?TME=>^S\]6+*V6,=78T/K>"U['"00='-<T_2:Y2224UL/IV)A
M;_L["#:0;'/>^QSMH]-FZRYUC_8P;46RFJUU;K&[G4NWUGP=M=7N_P`RQZ(D
MDI2K8?3L/!+CC5[-X:TRYSH8S=Z5-?J.?Z5%6]_I45?H:O\`!L5E))2+)QJ<
MJKTK@2V0X%KG,<"#+7,MJ<RQG]AZ?'QZ<:BO'H8*Z:FAK&#@`(B22G__U/54
MDDDE*22224I))))2DDDDE*22224I))))2DDDDE*22224I))))2DDDDE/_]7U
M5))))2DDDDE*22224I))))2DDDDE*22224I))))2DDDDE*22224I))))3__9
M.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S
M`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`
M4P`S`````0`X0DE-!`8```````<`"`````$!`/_A#]!H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-
M,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^#0H\>#IX;7!M971A('AM;&YS.G@]
M(F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835`@0V]R92`T+C$M
M8S`S-B`T-BXR-S8W,C`L($UO;B!&96(@,3D@,C`P-R`R,CHT,#HP."`@("`@
M("`@(CX-"@D\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N=S,N;W)G
M+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@T*"0D\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C
M+V5L96UE;G1S+S$N,2\B('AM;&YS.GAA<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+R(@>&UL;G,Z>&%P34T](FAT='`Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIP:&]T;W-H;W`]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B('AM;&YS.G1I
M9F8](FAT='`Z+R]N<RYA9&]B92YC;VTO=&EF9B\Q+C`O(B!X;6QN<SIE>&EF
M/2)H='1P.B\O;G,N861O8F4N8V]M+V5X:68O,2XP+R(@9&,Z9F]R;6%T/2)I
M;6%G92]J<&5G(B!X87`Z0W)E871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<"!#
M4S,@5VEN9&]W<R(@>&%P.D-R96%T941A=&4](C(P,3$M,3(M,3A4,3`Z,C@Z
M,34K,#$Z,#`B('AA<#I-;V1I9GE$871E/2(R,#$Q+3$R+3$X5#$P.C(X.C$U
M*S`Q.C`P(B!X87`Z365T861A=&%$871E/2(R,#$Q+3$R+3$X5#$P.C(X.C$U
M*S`Q.C`P(B!X87!-33I$;V-U;65N=$E$/2)U=6ED.C-$,$$Q-#%$-4$R.44Q
M,3$Y0D4S041#13A",C)"-C8R(B!X87!-33I);G-T86YC94E$/2)U=6ED.C-%
M,$$Q-#%$-4$R.44Q,3$Y0D4S041#13A",C)"-C8R(B!P:&]T;W-H;W`Z0V]L
M;W)-;V1E/2(S(B!P:&]T;W-H;W`Z24-#4')O9FEL93TB<U)'0B!)14,V,3DV
M-BTR+C$B('!H;W1O<VAO<#I(:7-T;W)Y/2(B('1I9F8Z3W)I96YT871I;VX]
M(C$B('1I9F8Z6%)E<V]L=71I;VX](C$P,#`P,#`O,3`P,#`B('1I9F8Z65)E
M<V]L=71I;VX](C$P,#`P,#`O,3`P,#`B('1I9F8Z4F5S;VQU=&EO;E5N:70]
M(C(B('1I9F8Z3F%T:79E1&EG97-T/2(R-38L,C4W+#(U."PR-3DL,C8R+#(W
M-"PR-S<L,C@T+#4S,"PU,S$L,C@R+#(X,RPR.38L,S`Q+#,Q."PS,3DL-3(Y
M+#4S,BPS,#8L,C<P+#(W,2PR-S(L,S`U+#,Q-2PS,S0S,CLT1#,X,$(Y1#@V
M0T4P,41",C8X1CDW,#9$1$5!0C)!,R(@97AI9CI0:7AE;%A$:6UE;G-I;VX]
M(C4Y,2(@97AI9CI0:7AE;%E$:6UE;G-I;VX](C,Y-"(@97AI9CI#;VQO<E-P
M86-E/2(Q(B!E>&EF.DYA=&EV941I9V5S=#TB,S8X-C0L-#`Y-C`L-#`Y-C$L
M,S<Q,C$L,S<Q,C(L-#`Y-C(L-#`Y-C,L,S<U,3`L-#`Y-C0L,S8X-C<L,S8X
M-C@L,S,T,S0L,S,T,S<L,S0X-3`L,S0X-3(L,S0X-34L,S0X-38L,S<S-S<L
M,S<S-S@L,S<S-SDL,S<S.#`L,S<S.#$L,S<S.#(L,S<S.#,L,S<S.#0L,S<S
M.#4L,S<S.#8L,S<S.38L-#$T.#,L-#$T.#0L-#$T.#8L-#$T.#<L-#$T.#@L
M-#$T.3(L-#$T.3,L-#$T.34L-#$W,C@L-#$W,CDL-#$W,S`L-#$Y.#4L-#$Y
M.#8L-#$Y.#<L-#$Y.#@L-#$Y.#DL-#$Y.3`L-#$Y.3$L-#$Y.3(L-#$Y.3,L
M-#$Y.30L-#$Y.34L-#$Y.38L-#(P,38L,"PR+#0L-2PV+#<L."PY+#$P+#$Q
M+#$R+#$S+#$T+#$U+#$V+#$W+#$X+#(P+#(R+#(S+#(T+#(U+#(V+#(W+#(X
M+#,P.T,U,D5%,30W-3<Y0C,S03E&,#`T,S<U-38T,#8Q-D1$(CX-"@D)"3QX
M87!-33I$97)I=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)U=6ED.C<T,D4X
M-T0Q-3DR.44Q,3$Y0D4S041#13A",C)"-C8R(B!S=%)E9CID;V-U;65N=$E$
M/2)U=6ED.C<T,D4X-T0Q-3DR.44Q,3$Y0D4S041#13A",C)"-C8R(B\^#0H)
M"3PO<F1F.D1E<V-R:7!T:6]N/@T*"3PO<F1F.E)$1CX-"CPO>#IX;7!M971A
M/@T*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@/#]X<&%C:V5T(&5N9#TG=R<_/O_B#%A)0T-?4%)/1DE,10`!
M`0``#$A,:6YO`A```&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94
M`````$E%0R!S4D="```````````````!``#VU@`!`````-,M2%`@(```````
M````````````````````````````````````````````````````````$6-P
M<G0```%0````,V1E<V,```&$````;'=T<'0```'P````%&)K<'0```($````
M%')865H```(8````%&=865H```(L````%&)865H```)`````%&1M;F0```)4
M````<&1M9&0```+$````B'9U960```-,````AG9I97<```/4````)&QU;6D`
M``/X````%&UE87,```0,````)'1E8V@```0P````#')44D,```0\```(#&=4
M4D,```0\```(#&)44D,```0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="
M($E%0S8Q.38V+3(N,0``````````````$G-21T(@245#-C$Y-C8M,BXQ````
M````````````````````````````````````````````````````````````
M``!865H@````````\U$``0````$6S%A96B``````````````````````6%E:
M(````````&^B```X]0```Y!865H@````````8ID``+>%```8VEA96B``````
M```DH```#X0``+;/9&5S8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H
M```````````````6245#(&AT='`Z+R]W=W<N:65C+F-H````````````````
M`````````````````````````````````````````````&1E<V,`````````
M+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@``````````````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@````````````````````````````!D97-C````````
M`"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M```````````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0``````````````````````````````````=FEE=P``````
M$Z3^`!1?+@`0SQ0``^W,``03"P`#7)X````!6%E:(```````3`E6`%````!7
M'^=M96%S``````````$````````````````````````"CP````)S:6<@````
M`$-25"!C=7)V````````!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!`
M`$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`
ML@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K
M`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!
MT0'9`>$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8
M`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#
ME@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V
M!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&
M%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9
M!ZP'OP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)
M9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1
M"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-
MC@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L
M$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02
MHQ+#$N,3`Q,C$T,38Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X
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M-C<V<C:N-NDW)#=@-YPWUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[
M:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G
M02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&
M\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"
M34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3
MJE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI6
M6J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]A
MHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL
M:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9P
MX'$Z<95Q\')+<J9S`7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,
M>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!
M:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^
MBF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.3
M39.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)
MG/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJF
MBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!U
ML.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[
M+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(
MQD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1
M/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*
MW1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+H
MO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"
M]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____;`$,`
M`@$!`@$!`@("`@("`@(#!0,#`P,#!@0$`P4'!@<'!P8'!P@)"PD("`H(!P<*
M#0H*"PP,#`P'"0X/#0P."PP,#/_;`$,!`@("`P,#!@,#!@P(!P@,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_`
M`!$(`&X",P,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&
M!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4
M,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)
M2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.D
MI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R
M\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U
M$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)
M(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JR
ML[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_
MV@`,`P$``A$#$0`_`/W\HHHH`****`"C-9VK>,-)T`D7^J:=9$<D3W*1X_[Z
M(K-OOBYX8T[PU?ZS-KVF+I6F?\?-TLZM%&>PR,Y8]@,DY``R145*D:<'4J.R
M6K;T27=LNG3G4DH4U=O1):MOLD='FBN%T#]IGX>>)[.WFM/&OAG-RH=(I=1B
MAF`*[L&-V#`@=01D<^E=CIFLV>MV_G65W;7D6<;X95D7\P:Y\+F&%Q*OAZD9
M_P"%I_DSHQ.`Q.'=L13E#U37YHLT49HS76<@449HH`****`"BBB@`HHHH`**
M**`"BF7%Q'9V\DTTB111*7=W8*J*!DDD]`!WKQ?QS_P4?^`7PWNIK?6/C#\.
M[>ZMSB6"+7(+B:,Y`P4B9F!Y!P1G'/3F@#VNBO%?!7_!1SX!_$6[AMM'^,7P
MZN;JXQY4$FNV\$TA]`DC*Q/'3&?:O9K.\AU&TCN+>6*>"90\<D;!D=3T((X(
M/J*`)**JZKKMCH4:/?7MI9)(<*T\JQACZ#<1FJ/_``L/P_\`]!S1_P#P-C_Q
MH`V**AT_4[;5[59[2X@NH'R!)$X=#CKR.*FH`***S]3\6:5HMR(;W4]/M)B-
MP2:X2-L>N"<XH`T**Q_^%AZ!_P!!S1__``,C_P`:EO/&VBZ?<-#<:OI<$R8W
M))=1JRY&>03Z4`:=%9VG>,-(U>[6WM-5TVZG<$B.&Y1W..O`.:T:`"BBJ>K>
M(=/T'R_MU]9V7FYV>?,L>_&,XW$9QD?F*`+E%94/CW0KF9(X]:TF221@JJMW
M&68GH`,\FGW_`(RT?2KM[>ZU73;:>/&Z.6Y1'7(R,@G(X(/XT`:5%8__``L/
MP_\`]!S1_P#P,C_QH_X6'X?_`.@YH_\`X&1_XT`;%%8__"P_#_\`T'-'_P#`
MR/\`QH_X6'X?_P"@YH__`(&1_P"-`&Q16;8^--&U.Z2"VU;3+B>0X2.*Z1W;
MC/`!R:;=>.-$L;F2&?6-+AFB8JZ/=QJR$=B"<@T`:E%4-,\6:5K5R8;+4]/N
MY@N[9#<)(V/7`.<5?H`***H:GXLTK1;D0WNIZ?:3%=VR:X2-L>N"<XH`OT5E
MVOCC1+ZYCA@UC2YII6"HB7<;,Y/8`')-6-5\2:=H+(M]?V5D9<E!/.L9;'7&
MXC-`%RBL?_A8?A__`*#FC_\`@9'_`(T?\+#\/_\`0<T?_P`#(_\`&@#8HK'_
M`.%A^'_^@YH__@9'_C1_PL/P_P#]!S1__`R/_&@#8HK-A\9:/<VD]Q'JNFR0
M6VWSI%N4*1;CA=QS@9/`SUJ'_A8?A_\`Z#FC_P#@9'_C0!L45C_\+#\/_P#0
M<T?_`,#(_P#&C_A8?A__`*#FC_\`@9'_`(T`;%%8_P#PL/P__P!!S1__``,C
M_P`:/^%A^'_^@YH__@9'_C0!L452'B33CI1OQ?V1L5.#<>>OE#G'WLXZ\=>M
M5/\`A8?A_P#Z#FC_`/@9'_C0!L45#8:C;ZK:)<6L\-S!)G;)$X=&P<'!'!Y!
M'X5-0`44,P12S$!1R2>`*\?^('_!0/X&_"R\EM=?^+GP\TZ\@#&2V;7;9[A,
M=08T<N#Z#&21@9-`'L&:*\/\$_\`!2W]G[XAWD=OI7QC^'DMS,2L<,^M0VLD
MAR!A5E922<\`<GMWKVK3]1M]6LHKFTGANK:=0\<L3ATD4]""."/<4`3449HH
M`****`"BBO)/VJ_C++\/?#L6DZ;*8M5U9&S(IPUM#T+#T9CD`]L,>H%-*XFR
M7XR?M3Z7\.;B73M-C35M6C^5P&Q!;GT9AU8?W1^)!KP#Q9\<?%_Q$NC'/JEX
M$E.%M;/,4?TVKRW_``(DUR^BZ//K^IQ6L`S)*>IZ*.Y/M7T)\#_@3;SQ"9U*
M6L9VRS8Q)<-W4>B_YZY-:62)NV>0>'/@KK7B295$1C=^=@4RR?7"_P!37HGC
MS]D&_P#C;X;TG3M<EO\`3K?2$V6PL98X+<9ZN]N=RF0YY8;2>^:^B]*T>UT.
MT$%I;Q6\2_PH,9]R>Y]S5FO,S7+<+F.&EA,;#GIRW6J_)IGH9;F.)R_$1Q6$
MFX3CLU;]3X8\1_\`!+_6-.U..&QOC>VTK;1<><H$7H74KD#/]W=]:R;K_@G5
M\0_!MR;O1KN19X^DEI<+'(/H0ZM^0K[]HK\IJ>"&1.4ITJM6%W=6E'W?)7BW
M;U;?F?H5+Q<X@BE&<HR76\;W]=?^!Y'P'#XW_:#^!3H)]4U2[MHSCR]4C-PD
M@]-\RY_[Y>O5K+_@HZOPY^&_AK5_B'X>N[:?7K^[LRVEQ$I$L"P'S=CMR"9L
M<.3\IP#R!]1R1K*C(RAE88((R"/2N&^*?[.'A/XNZ#%I^I:<D$=L9&@:U`A\
MII-N\[0-C$E5SN4]*^EX.X-QV39BIXC,)U\+9KDDG=/2S3YFM.R2^9PYGQ=E
MV:4XPQ>"A3E>[G37*VK/=*W6V]R?X0?M"^"_CQIANO"GB&PU;8NZ2!&,=S"/
M]N)L.H]R,'L:[7-?!'QF_P""8NN_#[4_[?\``6HW27-FQEAETYF@NH".X0'/
MMF-L_P"S4?P?_P""DWC7X(:G'HOQ6TN;7M+1_)75[6,)=PX./G7A9,8Z'8_4
MDL>*_6*F5*I'VF#GSKMU_K[CQ:O#\*T'5RVI[1?RO22_S_#T/OO-%<[\,OBK
MX=^,?A2'6_#.K6FL:;/P)86.4;NKJ<,C#^ZP!Y'%=%FO(E%Q=I*S/FIPE"3C
M-6:Z,****DD****`"O)_VUOVP?"_[#'[/FK_`!`\5&6:VLBMO96,+`3ZI=N#
MY5O&3P"VUB3SM1';!VXKUBOQO_X.G_B%J$GB_P"$7A-9'CTN&SO]6>,.=L\S
M/%$I9?5%1\'_`*:M30'PG^VQ_P`%,/BS^W;XFN9_%WB&YM/#ID)M/#FG2-!I
M=HH.5!C!_>N/^>DNYNN"!@#P_P`-^$=6\97YM-'TS4=5NL9\FSMGGDQC.=J@
MGH#6K\&O"NF^.OB]X4T/6+PZ=I&LZQ:6-]=;U0VT$LZ)))N;@;58G)X&*_JM
M^#?P1\)?L]^`K'PQX*\/Z7X;T/3XUCBM;*`1AL`#>Y^])(<99W)9B222235-
MV`_DWU?1+WP_>FVO[.ZL;A1DQ7$31..<=&`/4'\J]B_9`_X*%_%C]A_Q1;WW
M@7Q3>V^F)('N=#O':XTF^&<LLD!.T$]-Z;9!DX89-?TL_'O]F_P-^T_X$NO#
M7CSPSI7B32KJ-DVW4`:6W)&-\,GWXG'4.A#`CK7\W'[27_!.CXG?!3X_^,?"
M6D^`_'OB'2-`U:XL[#4[;0;F>*_MED/DRAXXRA+1[2=O`)([4D[@?LS<:MX#
M_P""_?\`P3<U&*QBCT3Q%!(1'%<$22^&];ACW(=P&6@</MW@`M%(PPK@A?P`
M\?\`@/6/A;XXU?PWK]A/I>MZ#=RV-]:3#$EO-&Q5T/T(/(X/49%?J3_P;;^$
M/B7\$_VH/&N@^)/!OC3P[X:\2^'/M+2ZEH]S:6S7EM<1"(;I$5=WESW'N?SK
MJ/\`@Y`_X)VG4+.']H#PI8YFMEBL/%\$29+IQ';WQ_W?EB?V\H]F-*X'F?\`
MP;H?\%#3\)/BG+\$/%-\5\.>-;@S^'I96RMCJ9`!@!/1+A0`!T\U5`&9&-?M
M_7\A6F:E<:-J-O>6D\MM=VDJS031,4>%U(*LI'(((!!%?TI?\$D/V^;;]OK]
ME/3]7O;B(^-_#6S2O$UNN%8W`7Y+D*.B3J-XP``PD4?<IM`>X_M!?'3P_P#L
MS_!?Q)X[\477V70_#-D]Y<$8WRD<)$@)`,DCE449&6<"OY>OVL?VF/$'[7_[
M0?B;XA>)I2VH^(+HR1P!BT=A;CY8;>//\$<851W."3DDD_>W_!Q?_P`%#!\7
MOBM%\$_"U\)/#?@BX\_Q!+"WRWNJ`$>02#ADMU)!'_/5G!&8P:_.7X3_``LU
MWXW?$K0_"'AFPDU/7_$5Y'8V-M'P9)'.!D]%4<EF/"@$G`%"0'UY_P`$-_\`
M@GA_PVM^TRFO^(['S_AW\/I(K[4UE3,6IW1)-O9\\,I*[Y!R-B;3CS%-<1_P
M6N54_P""HOQ<"@`+J%J`,8Q_H-M7[[_L+?L@Z'^PY^S/X=^'VB>7.^GQ>?JE
M\$VMJ=](`9[@@\@%@`H.=J*B\[:_`G_@MC_RE'^+O_80M?\`TAMJ$!X)\"_C
M5X@_9S^+_AWQQX6O#8Z_X9O4O;23&5)'#(X_B1U+(R]U9AWK^GS]B[]J_P`/
M_MK_`+./ASXA^'66*#5X=EY9F0/)IEVGRS6[X[JW0D#<A1L885_*OFON3_@A
MG_P49/[%G[1H\,^)=1,'PX\?S1VNH&5_W.E7GW8+SGA5Y\N0\#8P8Y\M:&@/
MZ&*_('_@ZS_YH-V_Y&'_`-Q=?KZKAU#*05;D$<@U^07_``=:?\T%_P"Y@_\`
M<720'YD?L<'_`(R[^%?;_BL-(_\`2V&O>/\`@O2?^-L/Q6_[A'_IGL:\'_8Y
M_P"3N_A7_P!CAI/_`*6PU_23\6_^"<GP.^/'Q"U#Q9XQ^&GAOQ!XCU;R_M=_
M=1N99_+B2)-Q#`?+&B*..BBFP/Y;Z*_IM_X="_LT?]$<\'_]^9/_`(NOQ!_X
M+6?!7PI^S[_P4)\5^%O!>AV/ASP_966GR06-HI$4326D3N1DD\L23[FA,#Y0
MHKZ(_P""3_PM\/?&O_@H5\-/"WBO2;37/#VKWMQ'>6-R"8KA5M)W`8`@\,JG
MKU%?O+_PZ%_9H_Z(YX/_`._,G_Q=%P/PY_X(G9'_``5'^$70_P#$PNO_`$AN
M:X__`(*@X_X>*?&GCKXPU'_T>U?T*_"[_@FQ\"?@IX^TWQ3X4^&/AK0_$.D.
MTEG?6T;B6W9D9"5RQ'*LP^AK^>K_`(*@_P#*13XU?]CAJ/\`Z/:A,#Z0_P"#
M:;/_``\3O>G_`")]_P#^C[6OWUK\"O\`@VE_Y2)WO_8GW_\`Z/M:_?6DT`5^
M!7_!RSG_`(>)V73_`)$^P_\`1]U7[ZU^!7_!RU_RD3LO^Q/L/_1]U0D!\W_\
M$OL?\/%/@MQT\8:=_P"CUK[O_P"#J?\`Y'_X,'UT_5?_`$9:U\(?\$OO^4BG
MP5_['#3O_1ZU]W_\'4__`"/_`,&/^P?JO_HRUIO<#\F:*U/!-G%J/C/2+>=%
MEAGO88Y$;HRF100?PK^EG_AT+^S1_P!$<\'_`/?F3_XNFW8#^9*BOZ;?^'0O
M[-'_`$1SP?\`]^9/_BZ/^'0O[-'_`$1SP?\`]^9/_BZ5P/Q1_8TR/^"3_P"V
MAD?]"1_Z>)J^0*_J1\,_\$Y/@=X-^'WB?PII?PT\-V7ASQG]E_MNPCC<0ZE]
MEE,MOY@W9/ER$L,$<FN;_P"'0O[-'_1'/!__`'YD_P#BZ$P/YDJ*_=+_`(+&
M_P#!.3X'?`;_`()P_$;Q9X/^&GAOP_XCTK^S/LE_:Q.)8/,U2TB?:2Q'S1NZ
MGV8U^%M-`%%?NE_P1R_X)R?`[X\_\$X?ASXL\8?#3PWX@\1ZK_:?VN_NHG,L
M_EZI=Q)N(8#Y8T11[**^F_\`AT+^S1_T1SP?_P!^9/\`XNDF!^?/AD?\<K'B
M'T_M!/\`U)K>OR8K^A7_`(+#?!7PI^S[_P`$8?B9X6\%Z'8^'/#]D^F206-H
MI6*)I-;LG<C))Y8DGW-?SU41`_H]_P"""W_*)[X4]?\`F+_^GB^KU#]O3]O7
MP7_P3[^"\OBOQ9*]W?7;-;Z-HT$@6ZUBX`!V)G.U%R"\A!"`C@LRJWEW_!!J
M58?^"37PK=V5$0:N6).`!_;%]R:_%/\`X*H_MN7G[=?[7GB'Q-'=S2>%-*E;
M2O#5L6.R&RC8A90O9YFS*W?YPN2%&$D`O[;/_!57XP_MS:W=IXC\1W6C^%9'
M;[/X;TF5K?3XD.<"0`YG8`\M*6ZG`4';7S=CL*]]_P""<G[!'B#_`(*%_M#V
MO@[2ISI>CV<7V[7=6,>]=.M`P!('1I7)"HO<G)PJL1_03^S5_P`$T_@E^RCX
M;M+'PI\/]`>\M@"^KZE:1W^J7#C&7:XD4L,D9VIM0'[JKTIWL!_+SS@5[/\`
MLD?\%`?BO^Q)XEBOO`/BN^LK'S`]SHURQN-*OAGD26[';D\C>NUQDX8$U_1O
M\?\`]@GX/?M/>&[C3?&?P^\-:D+A<+>1V:6U_`<8#1W$8652!CHV#@9!'%?S
M^_\`!5/_`()U:A_P3G_:&708KNXU?P?X@@:_\/:E.`)I8@0LD,NT!?-B8@$J
M`&5D;"[BJC=P/W+_`."9_P#P4I\*_P#!1KX12ZKIT":)XMT0K%KVA/,)'M&;
M.V6-L`O`^#M;`((93R`3]*U_,?\`\$HOVIKW]D?]NKP+XBBN6@T?5;Z/0M<0
MG$<UC=.L;EO^N;%)A_M0KVR*_IPI,`HHHI`%?&_[4.N2:W\;-8#LQCLREM&I
M_A"H,C\6+'\:^R*^,OVE],DTKXW:\C@D32K.I[$.BM^F<?45=/<F19^#.C!;
M"XO2N99I/)3UP,9Q]2?_`!VOKC0=)30=%M;.,`+;QA..YQR?Q.3^-?+/PEG"
M^$H&0#=%*^?KNS_+%?5ME=I?V4,\9!CG19%/7((R*)A$EHHHJ"@HHHH`****
M``\UYM\=?V7O#/QWTN9=0M(K;4I$VB\BB4LW'`D4\2+['D=B*])HK2E5G3DI
MP=F;4,14HS52E*S78_,7QU\)/B/^P!\3/[<\)W4]K$QW-$FZ:SU&('E2I^^O
M/*G#IG(/((^ROV/_`-N'PW^U7H@MT,>C^*[2,/=Z5)("7'>2$G[\?KW7(![$
M^K^//`>E_$GPS<:3J]JMS:7`^CQ-V=#_``L.Q_ID5^8/[2?P8U#]GSXMS:UX
M2U"[M]1T.?[2D\4,EM,!U$H1U!!QG<,%6!)&03GZ"DZ>90<:BM477OZ_UZ'V
M>'G0SNFZ=9<M:*TDMGZ_UZ=3]5\CU%%?-?['O_!1+PW\>?#>G:9XCO+30_&K
MS)9-:G(CU*1N%DAZ\,>JG[I]1@U]*9KP:^'J49N%169\AC,%6PM1TJ\;-?CZ
M=T%%%%8G*%?G+_P<6_L.ZW^T?^S]H'Q`\*:?<:IK?PV>X:_L[="\UQILP0RR
M*HY8PO$C;0/N/*?X<']&J,'.::8'\@>._%?67[,/_!;#]H3]EC2K+2M-\71>
M)]`T]%C@TKQ);_VA#$BC"HLN5N%0#@*LH4#H*_6S]LW_`(()?!3]J_6;W7M+
M@O/AQXJOF:6:\T-$^QW4IZO+:-\A)/),1C+'))))-?`'QM_X-F/C7X&\Z?P;
MX@\'^.[5,[(O.;2[V3T^24&(?]_J;:`]K^"7_!TSI\WDV_Q'^%=Y;8QYM]X;
MU%9MWKMMIPF/QG.?;J?M']F'_@L=^S[^U;J=KI>A>-X=%U^\8)%I.OPG3KF1
MCT5&?]U(QZ!4D9N.G3/\_P!\>?V#_C)^S'#-<>._AOXK\/V,#;7OY+)IK!23
M@#[3'NA))]'YKR7Z4^4#^OSOUZ5F^,?!^E_$'PGJ>@ZW8V^IZ/K-K)97MI.N
MZ*YAD4JZ,/0J2*_(/_@WZ_X*H^)-6^)%G\"OB%K-UK=AJ<##PGJ%[*9+BREB
M1G-DSGEHFC4F/<<H4"#(90G['5`'\P7_``4K_8<U/]@/]J;6?!EQ]HN=`N?^
M)CX>OY!S>V$C-LR1QYB$-&_3YD)P`PK%_8J_;G\<_L'>/=9\0^![N**XUS1[
MC2;F&==\+;T/DS;3QYD,NR121SM*GY78']YO^"PO_!/N']OC]EB[M-+MX?\`
MA/?"(DU/PW.1AI7VCS;,G^[.BA1T`D6)CPI!_FWN+>2SN)(9HWBEB8HZ.I5D
M8'!!!Z$'M5+4"34M2N-9U&XO+R>6ZNKN1IIII6+O*['+,Q/)))))/4FOV<_X
M-QO^"=H\$^#Y?CWXKL=NK:]%)9>%(9D&ZULR=LUY@\AI2&C4X!\M6(RLHK\\
M/^"5G[!E[^W_`/M5:7X:FCN(O"&C;=3\37<>5\JS5A^Y5ATEF;$:]P"SX(0B
MOZ7=!T&R\+:%9:7IMK!8Z=IL$=K:VT*!(K>)%"HB@<!54``#H!1)@6Z_FJ_X
M+8_\I1_B[_V$+7_TAMJ_I5K^:K_@MC_RE'^+O_80M?\`TAMJ2`9_P2G_`&)[
M#]OCXE?$KP+/(EMK$7@&[U30+MR0EIJ,5]8")FQ_`RN\;<'"RL0,@5\W^-_!
M6K?#;QCJGA_7M/N=*UO1+J2QOK.==LMM-&Q1T8>H8$<5^A?_``:__P#)_7B_
M_LG]Y_Z<=-KV;_@XZ_X)RBYMU_:!\)61\Z(167C"WA3[Z\1P7W'<?+$_MY1X
MPQIWLP/:O^"`'_!1H_M0_`H_#+Q3?"7QU\.[6..VEE?,FKZ6,)'+SRTD)VQ.
M>X,3$DLQ'AW_``=:'_D@O_<P_P#N+K\O?V9?VBO$?[*'QS\.>/\`PK<?9]9\
M.W0G16)\NZC/RR02`=8Y$+(P]&.,$`U^@?\`P<(_M(^&_P!K;X#_`+,?Q!\*
MW!FTCQ%:Z_-Y;D>;9RC^S%EMY`.DD;AE/8E<C(()+:@?`_['/_)W?PK_`.QP
MTG_TMAK^K6OY2OV.?^3N_A7_`-CAI/\`Z6PU_5K1(`K^=K_@X/\`^4H_C7_L
M'Z7_`.D,-?T2U_.U_P`'!_\`RE'\:_\`8/TO_P!(8:2`X_\`X(G?\I1_A%_V
M$+K_`-(;FOZ5:_FJ_P"")W_*4?X1?]A"Z_\`2&YK^E6A@%?R]?\`!4'_`)2*
M?&K_`+'#4?\`T>U?U"U_+U_P5!_Y2*?&K_L<-1_]'M0@(_\`@GQ^W+JW_!/K
MX\3>/-&T+3O$5Y+I4^E&UO9GBC"RO&Y?*<Y'ECCW-?;?_$4UX_\`^B5^#_\`
MP8W/^%?!G[&'[&/C#]NWXO2^"/!$NC1:S%I\NIL=3N7@A\J-D5AN5'.[,BX&
M/7FOJS_B&E_:*_Y_?AO_`.#F?_Y'IM(#T?\`XBFO'_\`T2OP?_X,;G_"OB3_
M`(*#_MRZM_P4%^/$/CS6="T[P[>1:5!I0M;*9Y8RL3R.'R_.3YAX]A7TI_Q#
M2_M%?\_OPW_\',__`,CU\I_MG_L8^,/V$OB]%X(\;RZ-+K,NGQ:FITRY>>'R
MI&=5&YD0[LQMD8].:$D!N?\`!+[_`)2*?!7_`+'#3O\`T>M?=_\`P=3_`/(_
M_!C_`+!^J_\`HRUKX0_X)??\I%/@K_V.&G?^CUK[O_X.I_\`D?\`X,?]@_5?
M_1EK0]P/RF\.:J-"\0V%^T9E%E<QSE`<%MK!L9[9Q7[$_P#$5/X?_P"B,:Q_
MX4<?_P`CU^..D:9)K6K6ME"4$UW*L$>XX7<S`#/MDU]__P#$-+^T5_S^_#?_
M`,',_P#\CTV!]'_\14_A_P#Z(QK'_A1Q_P#R/1_Q%3^'_P#HC&L?^%''_P#(
M]?.'_$-+^T5_S^_#?_P<S_\`R/1_Q#2_M%?\_OPW_P#!S/\`_(]+0#]IOV-?
MVE(/VP/V9O"?Q)MM(ET&#Q3!+.MA)<"X>WV3R18+A5#9\O/0=:]/KQ'_`()R
M?L]Z]^RK^Q3X"^'WB=]/DU[PU:30W;6,K36Y9[F:4;695)&UQU`YS7MU2!\@
M?\%ZO^43WQ6_[A'_`*>+&OYPJ_H]_P""]7_*)[XK?]PC_P!/%C7\X55$#^CW
M_@@K_P`HGOA3_P!Q?_T\7U?7]?('_!!7_E$]\*?^XO\`^GB^KZ_J0/D#_@O5
M_P`HGOBM_P!PC_T\6-?SA5_1[_P7J_Y1/?%;_N$?^GBQK^<*JB!^Y?[(WQ-N
M/@__`,&T%QK]I,;>\M_#/B*VMI@VUH99]5OK>-U/]Y7E!'N!7X:5^T?PGT"X
M\1_\&L]W;VPW21Z-JMT1@GY(?$-Q,_3_`&4:OQ<IQ`_=S_@V6^#=GX._8K\0
M^,3$IU3QIXBEC>7;@_9K2-8XD]\2/<'/3Y\=N?T@KX4_X-T/%5MXB_X)G:-9
MP,AET'7=2L;@!LE7:47`!X&#LG3CGC!SS@?==0V`5POQK_9D^'O[2$.G1^/O
M!GASQ@FD-(UD-5L8[H6AD"[RFX';NV)G'7:/2NZK!\>_%/PQ\*M/@N_%'B/0
M?#=K=2>3#-JFH16<<KX)VJTC*"V`3@<X%`'E$/\`P3$_9XMYDDC^#'PZCDC8
M,K+HD`92.A!V\&O=:\X_X;&^$/\`T53X;_\`A2V7_P`<KT6&9+F%)(W62.0!
ME93E6!Z$'N*`'4444`%?/7[;?@%O-TWQ)!&2NW[%=$#IR6C8_7+#/^[7T+6;
MXM\+6?C7PW>:5?1F2UO8S&X'5?1A[@X(]Q33LQ-'R5\$;J6YBO[)(Y9%A`N/
ME4L$'"DG'3G;7TC\%O%2ZKH1T^5Q]HL?N@]6C)X/X'C\J\R^#?A.^^`6E_$G
M4M0C!FT&P,L#C(2X1(Y9=PXZ':GK@Y'45E?#7]JZQU=;/5-1TB"5V&[[78'R
M9?0ATSM8]CR*^<SSB[+<JQ%/#X^;BYIM.S:TTUM=J_I;NS)UHQDH-ZO4^F**
MY;P?\:/#7CC8ECJD`N'X%O.?*ESZ`-][_@.:ZFO7P>/PV+IJMA:BG%]8M-?@
M:II[!11176,****`"BBB@`KD_BY\)](^*WA6XM=1TJVU"YCB<VC/(8)$DP=H
M$H5B@)QGY6'JK=*ZRC-5&<HOFB[-&E*K*G-3@[-?UT/RW_86\.>%/%W[:UC?
MZ-JD5C'X2N+V;7/#NK/'::UH%Q!%*CH\.2)HDFP/-@+J!C<(R<5]^?LA?M2^
M'/VS?V?/#WQ#\+M+'I^MQ'S;64@S6%PA*RV\F/XD<$9Z,-K#A@:_'S_@OA\%
MC\)OVZ+GQ'HDDNG3>*]*MM>66U<Q/#<*7MI2"N"&;R0Y(ZF0GKFNM_X-M?VF
M;CP%\<O$GPFO[ESI/C.U;5=+B9LK#?VR$R!1V\RW#%CS_P`>R>]?/2XGQ%?'
M1PN+M>-XW77^5V[OKZG](<5^&-+'<+_ZV9?4<DZ=.HH/[,5S>UC?[7*W=.R:
M4&G=NY^T5%%%>^?S6%?B9_P5>_X*O_M)_LJ?M\^/?!/A;Q^=$\,:9):2Z7:?
MV#IEP$AELX)<B2:V9V^=WR2QP01VK]LZ_,K_`(.#?^"8^L_M'^'M/^+_`(!T
MV75/%/A6Q-EKFF6R;I]2L$9I$FB4<O+"6<%>6=&&.8PK-`>%?\$E_P#@M1\8
M/B]^W!X7\'_%WX@P:MX6\5)-IL$<NCZ?9)'?,F;8^9!#&^7D41`9(+2@8Z$?
MM57\@T<DEI<*Z,\4T39#`E61@>OL0:^[OV;_`/@X@^/OP)\-6>BZS)X?^(FG
MV2+''/K\$IU!4&,*;B)T,AQ_%*'8YY)IM=@/Z"+BWCO+>2&:-)8I5*.CJ&5U
M(P00>"".U?SW_P#!P3^S5X%_9M_;:LH?`MA8Z+;>)]"BUC4-*LU5+>RN6GFC
M+1QKQ$KK&K;```=Q&`<#O_B1_P`'._QG\2Z3+;>'/"'@/PS+,NW[6T-Q?3PG
MGYD#R"//3[R,..ASQ^?OQ?\`C%XH^/OQ$U/Q;XRUN^\0^(M7D\R[OKI@7D(&
M````JJH``50%4`````4D@/2/^":JW[?\%"?@F--,GVC_`(3;22VP@'R?M<?G
M=>WE;\^V:_J.K\5?^#=G_@F_K7B/XJ6WQY\6:;<:?X=\/QRQ^%X[B)D;5;J1
M&C:Z4$?-#&C.`PX,A&#F,U^U5#`*_D;^(?\`R/\`KG_80N/_`$8U?UR5_(W\
M0_\`D?\`7?\`L(7'_HQJ<6!^IW_!JQ_R/_QGZ?\`(/TK_P!&W5?LM7XT_P#!
MJQ_R/_QG_P"P?I7_`*,NJ_9:DP"OYJO^"V/_`"E'^+O_`&$+7_TAMJ_I5K^:
MK_@MC_RE'^+O_80M?_2&VH0'O'_!K_\`\G]>+_\`LG]Y_P"G'3:_<WQ7X5TW
MQUX7U'1-8LK?4M(U>UDLKVTG0/%<PR*4>-@>JLI((]#7X9?\&P'_`"?SXO\`
M^R?WG_IQTVOW=HEN!_,;_P`%/?V#M3_X)_\`[46J>%G2>?POJ9;4?#=^_/VJ
MR9CA&;O+$?W;],E0V,.N?!KKQ=J=]X3L="FO9Y-(TR[N+ZUM"V8X)ITA2:11
MV+K;P`_]<UK^D[_@K!^P#8_\%`/V7+_1+>&&/QKX=$FI>&+ML*4N@OS6[,>D
M4ZC8W8,(W.=@%?S5Z[H=[X7UN]TS4K6>QU'3IWMKJVG0QRV\J,5=&4\AE8$$
M'H0:J+`[S]CG_D[OX5_]CAI/_I;#7]6M?RE?L<_\G=_"O_L<-)_]+8:_JUI2
M8!7\[7_!P?\`\I1_&O\`V#]+_P#2&&OZ):_G:_X.#_\`E*/XU_[!^E_^D,-)
M`<?_`,$3O^4H_P`(O^PA=?\`I#<U_2K7\U7_``1._P"4H_PB_P"PA=?^D-S7
M]*M#`*_EZ_X*@_\`*13XU?\`8X:C_P"CVK^H6OY>O^"H/_*13XU?]CAJ/_H]
MJ$!](?\`!M+_`,I%+W_L3[__`-'VM?OK7X%?\&TO_*12]_[$^_\`_1]K7[ZT
M2W`*_`K_`(.6O^4BEE_V)]A_Z/NJ_?6OP*_X.6O^4BEE_P!B?8?^C[JB.X'S
M?_P2^_Y2*?!7_L<-._\`1ZU]W_\`!U/_`,C_`/!C_L'ZK_Z,M:^$/^"7W_*1
M3X*_]CAIW_H]:^[_`/@ZG_Y'_P"#'_8/U7_T9:TV]0/RQ^'G_(_Z'_V$+?\`
M]&+7]<E?R$65[+IUY#<0.T<T#B2-QU5@<@_G7T5_P]X_:7_Z+'XP_P"_T?\`
M\31(#^FVBOYDO^'O'[2__18_&'_?Z/\`^)H_X>\?M+_]%C\8?]_H_P#XFE8#
M^FVBOR/_`.#>W]M_XL_M0_M,>-=(^(/CO7?%>F:?X8-Y;6]](K)#-]K@3>,`
M<[68?C7ZX4-`?('_``7J_P"43WQ6_P"X1_Z>+&OYPJ_H]_X+T_\`*)[XK?\`
M<(_]/%C7\X5.+`_H]_X(*_\`*)[X4_\`<7_]/%]7U_7R!_P06_Y1/?"G_N+_
M`/IXOJ^OZD#Y`_X+U?\`*)[XK?\`<(_]/%C7\X5?T>_\%Z?^43WQ6_[A'_IX
ML:_G"JHL#^A[_@C9\.;#XP?\$3O!GA+559M+\4:7X@TF[``)\J?4]0B?&>^U
MC7X#_&;X3:S\"/BQXC\&>((#;:SX8U";3;M,':7C<KN7/5&`#*>ZL#WK^A?_
M`((+?\HGOA3_`-Q?_P!/%]7A_P#P71_X)"7_`.U#!+\7/AI8_:?'>EV@BUG1
MH8\R^(+>,822+'WKF-?EV]9$"J/F55=)V`^4O^#>#_@H+I/[-7QAUGX9^,=2
MBTWPQ\098IM.N[APEO8ZH@V!7)X59TVIN/1HHAP"2/W<K^0F_L)]+OI[:YAF
MMKFV=HI894*21.I(96!Y!!!!!Y!KZI_9O_X+6_M$?LR>&[30]*\:#7M"L$6.
MVL/$%HFH+`B\!%E;$P0``!1)M`&`!3:`_I-K\,/^#DO]L[3/C5\??#WPP\.W
ML-]IWPX2>35IH6#1MJ4VT-#D<$PQH`<'AY9%(RE>-_';_@O+^TA\=?#-QH[^
M++'PEI]XACN!X<L193R+W`G)>9/K&Z_E7QP6>XF+,7DDD;))Y9B3^I)H2`[;
M]FCX*WW[1O[07@SP+IR2-=>*M7M].W)UBC>0"20^R1[G)[!37]7]E9Q:=9PV
M\"+%#`@CC0=%4#`'X"OR\_X("?\`!*75?@.@^-?Q&TR33O$VJ6;0>&M*N$*S
MZ7;2KB2ZE4\I+*AVJAY6-GW<OA?U(I-@%%%%(`HHHH`\K_;6\0?\([^R]XNF
M!.^>V2T51]YS+*D>!Z\,?PK\_O!7C>^^&.L&SU2VN[:VGVO+#-&R21A@"L@4
MC/((/N,>U?JE+`LI7>BOM8,,C.#Z_6O,OVEOV5]`_:1\/^7?(+#6K5"MEJ<2
M`RP]PC_WX\_PGIDD$$FOS+CW@>OG4EBJ%3WH124&M'JV_>OHW=6TMIJ]=/(S
M#`U:DU6I2LTM%W/E>PUBWO8X+J(Q75L^'&&.R1<],CD9Z<<U]:?`;XN>'?&N
M@0:=IC&PO+5,-83SM)(!W*,Q)=??J.X%?GUX[\(^-/V1?%K:7X@L9'TZ=R89
M4):UNP/XXGQPWJIP1W'0UTWA7XB6NOQQ7NE7CQSPD.-CE)H&'0G'(/H1^!K\
M=X<SK&\+XZ?/2NGI*+5I?)VNOR?;9KDP^9<LG&:M);I_H?I'FBOE7X5?MRW_
M`(>$5EXIMWU2U7Y1>0@+<H/]I>%?]#]:^A?A_P#%[PY\3[59-$U6UO'V[F@W
M;)X_]Z,X8?7&/>OZ(R+B_+,VBOJU2T_Y9:2^[KZJZ/8H8RE5TB]>W4Z6BBC-
M?3G4%%&:*`"HYED:%Q$Z)(5.QF4LJG'!(!&1[9'X4AU"W%\+4SPBZ:,RB'>/
M,*`@%MO7&2!GIDUYM^U/^U7X7_9.^'-SKNOW*R7;HPT_3(G'VG49>R(.R@D;
MG/"CU.`>C#82MB*L:%"+E*6B2W9Q8[,L-@L//%XJHH4X*\FWHO7_`"Z['Y`?
M\%=_V@]?^/7QKL]%\6>&H/#7B7P!:3Z-J4<$AD@O)#(76XA+?,(I(RCJK9(#
M?>;.:\!_X)\^*)OAG^W-\)=7@D>$1^*;"VE=<Y$,\RP2CCKF.1QCO7U)^V.]
M[^WI^SK:_&33](CD^('AF]_X1[QA8:;"Q,MO-(387:QC+;0&,!/+,P'9:\C_
M`&8/V!_CW>?%#PQXHT#X2>(;L^'M4M=5B368?[*M;KR9DE"E[AH\HVW!*G."
M<<U^8\1Y/F&6YY/"8F+<X26J5[K2ST6NG4_T3\,.->$N(_#&AC\!5IT:%2E.
M'+*:BHS:?/&\Y:>\[I-NR:3/Z`\T5@?#/7==\2^"+"]\2^'U\,:W.F;K34OD
MODMGST$R`!QWS@?2M^OT2,KI-'^?U:E*E4E3E9M-K1IK3LTVFNS3:?1A1^=%
M%49'R;^V-_P1;^!G[96JW6M:GH-QX4\5799Y=9\.R):37+G^.:(JT4I)Y+%-
MY_O#K7Q1XZ_X-6[^.ZFD\,_&2TFA;F*'4_#[1.G(X:2.=@W&3D(.PQWK]B:*
M:8'XS^%_^#5SQ'<W*?VU\8M$LH0WS?8M`EN6*X[;YHQDGCVZ\]*^I?V7/^#>
M'X$_`'6;75_$<>K_`!,U>U99$76V1-.1P<AA:Q@!Q_LS-(OM7WG11<"*RLX=
M.LXK>WABM[>W01Q11J$2-0,!5`X``&`!TJ6BBD`5^:>M_P#!L1\)-=UF\OI/
M'_Q&22\F>=E5K+:I9BQ`_<=.:_2RBG<#Y:_X)U_\$I?!O_!-W6?%5]X5\1^)
MM=D\60VT%RNJF`K"(6D92GEQKR?,.<YZ"OJ6BBD`5\&_M8?\$`OAM^US^T+X
MF^(VM>,_'&F:IXHGCGGMK(VHMXBD,<0"[XF;&(P>2>2:^\J*`/CW_@GW_P`$
M:/`G_!._XRZGXV\,>*?%NMZAJFBRZ))!JAMS"D4D\$Q<>7&IW!K=1UQACQTK
M["HHH`*^&_VR/^""GPI_;'^/6J?$&^UOQ3X6U77(XSJ%OI!MUM[J=1M,Y$D;
M$.RA0V#@E=W4DG[DHH`_.;X7_P#!M?\`"KX5?$SPYXHLO'?Q!N;OPWJ=MJD$
M4S6?ERO!*LJJV(0=I*`'!!QFOT9HHIW`*^(/VUO^"%7P\_;A_:%U;XC>(/%_
MC32-4U>&W@DMM.-L+=!#"L2D;XF;)"`G)ZU]OT4@/@W]D_\`X(!?#;]D;]H7
MPS\1M%\9^.-3U3PO/)/!;7IM3;REX9(B&V1*V,2$\$<@5]Y4447`*_/G]H/_
M`(-V?AA^T3\;_%?CO5/&_CRQU'Q;J<^J7%O:FT\F%Y7+%4W0EMH)XR2:_0:B
MBX'QG^P7_P`$4_`7_!/[XX2^._#7BOQ?K6HS:9-I9M]3-L8`DKQN6_=QJVX&
M,8YQR:^S*,T4`%?&?[>G_!%/P%_P4!^.$7COQ+XK\7Z+J,.F0Z6+?3#;"`I$
M\CAOWD;-N)D.><<"OLRB@#\^?V?/^#=GX8?L[?&_PIX[TOQOX\OM1\):G!JE
MO;W1M/)F>)PP5]L(;:2.<$&O8?\`@HI_P2E\&_\`!2+6?"M]XJ\1^)M"D\)P
MW,%LNE&`+,)FC9B_F1MR/+&,8ZFOJ6BG<#\R?^(7+X0_]%"^)'_?5E_\8H_X
MA<OA#_T4+XD?]]67_P`8K]-LT47`_,G_`(A<OA#_`-%"^)'_`'U9?_&*/^(7
M+X0_]%"^)'_?5E_\8K]-J*+@?(__``3U_P""/G@C_@G1\3-;\4>%_$_BO7+O
M7-,_LN6+5#;F*-/-27<OEQJ=V8P.3C!-?7%%&:0'F/[8W[+FD?MH_LX>(_AI
MKVHZEI6D^)?LWGW5AL%Q%Y%U#<KMWJR\M"H.0>">^#7PO_Q"Y?"'_HH7Q(_[
MZLO_`(Q7Z;9HIW`\Q_8Y_9<TC]B[]G#PY\--!U'4M5TGPU]I\BZO]AN)?/NI
MKEMVQ57AIF`P!P!WR:].HHI`>8_MC?LN:1^VC^SAXC^&FO:CJ6E:3XE^S>?=
M6&P7$7D74-RNW>K+RT*@Y!X)[X-?"_\`Q"Y?"'_HH7Q(_P"^K+_XQ7Z;447`
M\Q_8Y_9<TC]B[]G#PY\--!U'4M5TGPU]I\BZO]AN)?/NIKEMVQ57AIF`P!P!
MWR:].HHH`^9OVS?^"1_P3_;@O9]5\4>')-(\53+M/B#0Y19W\F!@&7AHICT&
M949@``"!7PM\0_\`@U<F%Y++X3^,436[$^7;ZMH!#QC(P#+%-AN,\B,=!QSQ
M^P5%-,#\;?!G_!JWK<]VA\0_&+2K2W5_F33M`DN'=>.`TDR!2>><'&!US@?:
MO[&7_!$KX'_L::S::]::1=^,O%MDPDAUCQ`Z7#6D@_C@A55BC(."&*LZXX?K
M7U[10V`?G11FBD`4444`%%%%`!1110!C^-_`6C?$GPY/I&O:;::KIMR,/!.F
MY<XP&'=6&>&!!'8BOB?]H'_@EQKOA#4)=<^%VHRWL29?^R[F81W47?$4IPL@
M[;7VG`ZN37WA17A9UPW@,TARXJ%VMI+22^?Z.Z\CCQ>`HXA6J+7NMS\BI/B]
MJO@76I-&\8Z1?:;J-J=DOF0&&5/=HVQ^8X]!73Z'XYM-6*7.E:@CRQG<K0R%
M9(SZX^\IK](_BK\#_"7QOT8V'BK0-.UJ``A&GCQ+#GO'(,.A]U(KY'^,7_!&
M33KVXEO?A_XKNM'GSNCL]44S1`YZ+,F'11[JY]Z_(,U\+<71DZF!ESK[G]ST
M^Y_(^;Q638J&M)\Z^Y_Y&!X._;1^('@-4C36!JMM'TAU&,7&?^!\2?\`CU>D
M>'_^"GTUN%36/"<4I'WI;.]*#\$=3_Z%7RC\0/V0_P!H7X*N_F>'+WQ+8QG"
MS:;C4Q)COM3]^!_O**\EUGX[ZWX3U!K/7?#DMG>)]^&426LB_P#`7!(KSZ.8
M\397^[=2:2Z25_NYT_P/'J9CF.&TO)>J_P`S]+;7_@J%X)\K-UH?BF)_2**"
M0?F95_E71_"']N[P[\<?B-9>&]`T/Q'Y]RCRR3W4<,<5NB*26;;(YQT`]2P'
MO7Y0S?M-V94EM+NE;T$JD?R%>R_L2_\`!2/P-^S]XCUV7Q'H?B**76;=+2#4
MK`0SO8IDELQN5R"VTD@G[@^4U]-DG%^;U\93IXR<84[^\^5;?+OMMH:8/B/&
MSKQC6DE"^KLNG3Y['H/[7?[4^OV_[9FH^(/"6KRZ?)X6A;0K.6,+(CJN1/E&
M!1P92Y&01\B'J!CYD^-/CBY\57USKGBO6+S5]1G',MU*9II`,X5<GA1G@#"C
MVKVB+]G+1/V@;MYOA'\7_"'BBXNR7_LK52VEZT6)^Z(YL^:V>K`*,_45X)\?
M?V7O'?P:OV/B_P`/:SI<;L$-[<Q-+;'G'$R;D;'HI)K^^N$L5D.*P]/^S:\)
MRC%1TLI-+UL][OU9_%O%^6<73QU;$Y[2J1H5*DJGNR<Z:<NTHMTTU&ROO96/
M(O`7[8GQ(_9B^(.K>(OA]K;^'+O4[)M.D'V>&Z3R2ZN#LE5D+AE!#;<C)`X)
M%?JG_P`$=?AA\:O$/AS4OBS\;?&/B[5=0\4VX@\/Z'J-VZ6UG9EE=KLVHQ&D
MDI"A/D#+&I/23`SOV'?^"-?@CP0^C>.O&VHZ9X_U*2..^TZVM1OT:$,`Z2Y/
M-SQ@@L%3G[AX-?>1SZ5^=\=<58'%2EAL!33D])5''5V^RFU>W=_):']7>%W!
M689=AZ=;,)N,(J\*2E=*_P!J23Y;]EKKJ]=!:***_+S]H"OSR_X+.V%MXO\`
MVO/V3_"FL>(]8\.>%?$^J:Y;:S+8ZL^F;X@NGD%I58`8).">FX^M?H;7YR?\
M%L=*\%ZY^V?^R#:?$1]$C\$W&K:\NL-J]PEO8B#9IN?-D=E55SCDD4`><?M^
M?`/P!^Q7\%D\??!#X[>/8?BA8ZG8V^@Z)!XV.L#Q!))=1H\!M<L\G[MV<KRI
M";2IW5^J'@V[U'4/"&DW&KVZ6FJSV<,E[`ARL,Y0&1![!LC\*_+'_@H=\.OV
M(/AY^R]XA\1?#/Q!\/-(^)FC1K/X6N?`WBA9]4CU`.#%A+:=CL)X9V7"C)!#
M`&OTA_93OO%6I_LQ_#RY\<QRQ>,[CPWI\FMK*-LJWAMHS-O&!A]^[<!P&R!Q
M3N!W]%%%(`KY,_X+E^(=0\*?\$M?BCJ&EWUYIM];_P!D^5<6LS0S1YU>R4[6
M4@C*D@X/()%?6=?('_!>K_E$]\5O^X1_Z>+&@#ZI\`2-+X$T1W9G=["`DDY)
M/EKS6M6/\/?^1`T/_L'V_P#Z+6MB@`HHHH`^;?\`@JS^UUK'[&O[(FH:]X6@
M2?QIXBO[?PWX<5E5PM]<EMK[6X8I&DKJI!!95!&W->5^"?\`@AWX.\2>`H+W
MXG^-OB9XN^)VHVZ3:GXD7Q1<Q/;79&2;9<[0B,<)YBMPHX'0=+_P6\^!GB7X
MQ_L70:IX1T^;6-?^&OB2Q\9V^G1(9)+U;42I(@4<MMCG=]HY(C(&3@'T3X,_
M\%//@;\9O@S9^-8/B3X/T6REMEFO;35=7@M+S2Y"N6AFC=@P=3D<`AL94L""
M0#RC_@F9\:O'7@?]H#XK?LV_$KQ#=^,=9^%OV?4/#_B&[RUWJND7"JR?:&)R
MTD8DARQ+',CJ6.P$_:E?!'_!-#6[K]KO]O?XX_M&Z?:W=I\/]5M;7P=X5FN(
MFB.KQ6_EF:Y"L`P7?"I&0/\`7%3\R-7WO0`4444`%?$'_!+#Q3JFO_MD?MAV
MU_J5_?6VF^/(XK2*>X>1+5-UW\L88D(.!P,#@5]OU^;W_!.[]HWX>?`G]MW]
ML2'QQX\\&>#9=2\?*]HFN:W;:<UTJ/=AC&)G7>%++DC.,CUI@?I#17%?"S]I
M7X<_'/4+NT\$>/\`P3XQN[",2W,.AZY:ZA);H3@,ZPNQ52>,G`S7:T@"BBB@
M#-\9>+++P%X0U77=2E\C3M%LYK^ZD_YYQ1(7=OP52:_.C]CG]D_4?^"MGA&Y
M^.OQU\1^,)M"\4:A<_\`"(^#=,UF:PTS2+"*5X5=A$59I2RN-P*E@H8E@X"_
MH3\6?`<?Q3^%GB;PQ+*8(O$>E76EO*!GRUGA>(M^`;-?#W_!'O\`:X\+?`_X
M!+\`OBAK6D^`?B;\)KZ[TNZT_6KI+%=0@:X>:*XMWE*K*A67`VG)"A\;64D`
MH6_AS7?^"2'[;GPN\,Z)XL\2^)?@=\;=0/AU=%UV_:^E\,ZH2JP-;2-R(W:1
M!M[C?NW,$(_1"OSO_:@^-6C_`/!0_P#X*)?`GX;?"[5+7Q3HGPD\1Q^/?%VN
MZ;(MQIUBUJR-;P+.N4=V8,A"DX,JC.5?;^B%`!1110`5\2_\%&/BCXZ^-7[5
M_P`./V8OA]XEO_!!\9Z;-XD\7^(;`F._LM(C=T6*W<'*-*\,J$CG)C!PA<'[
M:KX`_;O\1K^Q#_P5'^%_[0>NVMROPU\1^'9?`?B34X8FE7193,\T$\H`)",6
MC'R_PP28!;`8`O?%C_@B1X=\$?#2[UCX*>+_`(C^$/BMH=NUUH^K-XFGF&I7
M*#<(;E781[)2-I*A5!;)#*"A^NOV;=0\;ZI\"/"LWQ)T^TTOQX=/C37(+:6.
M6'[4ORNZ&,E-KXWX4D+OQVKXJ_X*-P?LB^/_``UK'Q4\1^,+3Q9XLO-+6WT7
M3_#7C29[G6)@C+;10VUK-R6<@%]N!G+&O4_^"$NHW&J_\$J?A9<75Q-<W$G]
MK;I)7+NV-8O0,D\G@`?A0!]<T444`%>>?M=7DVG?LH?$^YMYI;>X@\):K)')
M&Q1XV%G*0RD<@@\@BO0Z\X_;&_Y-$^*G_8GZM_Z134(#S_\`X).ZS>>(?^"<
MOPBO;^ZN;Z\N=!1Y9[B5I993O?EF8DD^YKZ'KYP_X)"_\HTO@Y_V+Z?^C'KZ
M/H`****`//?VL/CU;?LO?LV>-_B#=0"[3PGI$]_';EBHN9E7$41(Z!Y"BY[;
MLU\:?LJ?\$PHOVS?@OHOQ7_:)\5^.O%WC;X@6::S#80:Y<:?I_AZVN!YD$-O
M#"RA#Y1C9E/`8[=N06;ZG_X*'?`C4/VF?V)/B7X'TF,2ZOKFBRC3XB=HFN8B
M)H8\Y&-TD:KD\#//%>._\$S?^"C7PR\??LB>$-&\1^,/#G@WQEX$TJ#P_P"(
M-&UV_BTR[M+BSC6!I/+F924;8&R,A22IPRD`N!M?L'?L\?%[]DCXW>.?`VM:
M]JWC?X(FWBOO!NLZUJ276IZ;+E1)8."?,*`,V#M"?N00$+E:^KJ^4?V/_P!N
MK7?VS/VS/B7:>$8],U'X%>!]/BTZSUZ.U</JVLLT;/Y,Y;;)"B"4$*O>)L[7
M7=]74`%%%%`!7Y5Z_J7@;]KC_@IC\9?"/[2WQ'UCPEIG@N[M[+P/X4GU^30=
M+O+4JY:Z\P,@DF<>4X^8,1+CYU4*GZJ5\$I^T)\$?VO_`(\?$CX4_M,>#/AO
MX=\:^`];ELM#;7'2W?5M*/,$]M=2['#./G,:.,JZ$`X;#0':_L7_`+(OC?\`
M9$_:DU:U\'>*K[Q7^SAXDT-;NPM]4UK^T)]#U,2?<MR22860,21U\Q<Y*%C]
M@U^7?[,7A;P'^SG_`,%@_"/@G]FKQ5=ZO\./$/A_4+_QWH>G:NVL:-H[1PR?
M9YA*7<+(9A;J=S,R[PN<2;1^HE(`HHHH`****`"BBB@!"X!QS33,!GC-(V<'
MUJ"0D+R:`)C=*.H-,.H(O4&JD^XIE2`?>L+6FU((WV::W0]1N4F@#ICJD8[$
M_C5+7++3/$UF;;4K"SU"W/)BN85E3KZ,"*\F\63^/\L-.U?0X2.GFV[L/TKE
M;*;XQ"]S-XC\(-`3PJ6$P8#ZEJ;A=69+:>AZ+K/[(OP@\1S^;>?#+P+)+G)=
M=$MD9N,<E4!/`[UEV_[`_P`$(IY95^&'@]GF.6#V*.HY[*V0OX`5<\*S>,"%
M%_J6E3-CGRH64?K7<:6;LJOG21,?]D$5R2R_#-W=./W+_(Q>%H2U<%]R,OP5
M^SS\._AW<1R^'_`G@_1)XB"LMCH]O;R`@#G<J`D\#G.>*[.Y@AO[>2">*.:&
M52KQNH97!Z@@]156(G`R>:G0G`]*WITXP5H*WIH:QIQBN5))$/AWPWIWA+28
MM.TFPLM+T^`L8[:T@6"&,LQ9B$4`#+,S'`Y))ZFK],7[PI]:2DVVV[MCA!1B
MHQ5D@HHHI%!7'_%;]GKP!\>/L'_"<^!_!_C/^RO,^Q?V[HUMJ/V/S-OF>7YR
M-LW;$W;<9V+GH*["B@#S#PI^Q)\&/`?B&TU?0_A%\,-%U:PD$MM>V/A:QM[B
MV<=&21(@RL/4$&O3^E%%`!1110`5C^/?AYH'Q4\)W>@>*-"T?Q)H5_L^U:=J
MEE'>6EQL=9$WQ2!D;:ZJPR.&4$<@5L44`,M[:.TMXX88TBBB4(B(H544#```
MZ`#M3Z**`"BBB@`&>>*\4\:?\$W_`("_$/QO)XDUKX1^`]0UF>0RS7$FE1#[
M2YZM(@`61CW+@DU[710!4T'0+#PKHMKINEV5IING6,:PVUK:PK#!;HHP$1%`
M"J!T`&!5NBB@`HHHH`*\N\4?L/\`P6\;^([W6-;^$'PNUC5]3F:XO+Z]\*V%
MQ<W4K'+222/$6=B>22237J-%`'$_"S]FKX<_`S4+J[\$^`/!/@ZZOXQ#<S:'
MH=KI\EP@.0KM"BEE!YP<C-=M110`4444`%>;?'7]COX6?M-2V\OC_P``^%_%
M5S:+LANKZQ1[F%,YV+,`)`N>=H;!]*])HH`Y+X._`;P5^SYX:;1_`WA3P_X2
MTR1_,DM]+L8[99GQC>^P`NV.-S9..]=;110`4444`%4/$WA?3?&F@7>DZSIU
MAJ^E:A&8;JSO($N+>Y0]4>-P593Z$$5?HH`\=^&7_!/GX(?!GQROB7PO\*_!
M.BZ]$WF0WMOI<?FVK?WH<@^4>V8]IQ7IG@CP'H?PS\,V^B>&]%TGP]HUFTC0
M6&FVD=I:PF21I'*QQ@*I9W=C@<LQ)Y)-:U%`!1110`56UG1K/Q%I%WIVHVEM
M?V%_"]O<VUQ$LL-Q$ZE7C=&R&5E)!!!!!(-6:*`,SPAX-TCX>^&K+1=`TK3=
M#T;3H_)M+#3[9+:UM4SG:D:`*JY)X``YK3HHH`****`"O(OC!^P/\%OC]XM&
MO>,OACX.U_6R07O[C3D%Q/MZ"1U`,@`&`')&.*]=HH`QO`/P[T#X5^%;70O#
M&B:3X>T6Q&VWL--M$M;:$$Y.V-`%&3R>.36S110`4444`%>=_'/]DCX8_M,Q
MVX\?^`_"_BR6T&V"?4+!)+B!<YVI+CS%4GD@,`:]$HH`XGX)_LW>`/V;]#FT
HWP%X.\.^$;2Z*M<+IEC';M=%1A6E91ND8#/+DGFNVHHH`****`/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
